Document Report Card
Basic Information
ID: ALA4196003
Journal: Eur J Med Chem
Title: The selectivity and bioavailability improvement of novel oral anticoagulants: An overview.
Authors: Xie Z, Tian Y, Lv X, Xiao X, Zhan M, Cheng K, Li S, Liao C.
Abstract: Anticoagulants have exhibited a critical role in the prevention and/or treatment of thrombotic diseases. Up to now, kinds of novel oral anticoagulants, inhibiting plasma serine proteases in the coagulation cascade, have been developed to overcome the clinical limitations of classical anticoagulants (like warfarin and heparins). Some of them, such as Apixaban, Rivaroxaban, Edoxaban, and Dabigatran, have been approved by FDA in recent years. This review summarizes the discovery and optimization of representative novel oral anticoagulants with the aim to improve selectivity and bioavailability of compounds. The impact of different targets in the cascade on bleeding risk also is discussed. We hope some more effective, selective, and safer anticoagulants can be developed in the future on the basis of these design experiences.
CiteXplore: 29407959